All Relations between Neurodegenerative Diseases and substantia nigra compacta

Reference Sentence Publish Date Extraction Date Species
Bruk Getachew, Antonei B Csoka, Robert L Copeland, Kebreten F Manaye, Yousef Tizab. Dihydromyricetin Protects Against Salsolinol-Induced Toxicity in Dopaminergic Cell Line: Implication for Parkinson's Disease. Neurotoxicity research vol issue 2022 36585544 parkinson's disease (pd) is a progressive neurodegenerative disease associated with loss of dopaminergic neurons in the substantia nigra pars compacta. 2022-12-30 2023-01-05 Not clear
Giselle Prunell, Silvia Olivera-Brav. A Focus on Astrocyte Contribution to Parkinson's Disease Etiology. Biomolecules vol 12 issue 12 2022 36551173 parkinson's disease (pd) is an incurable neurodegenerative disease of high prevalence, characterized by the prominent death of dopaminergic neurons in the substantia nigra pars compacta, which produces dopamine deficiency, leading to classic motor symptoms. 2022-12-23 2022-12-28 Not clear
Xin-Yi Chen, Cui Liu, Yan Xue, Lei Che. Changed firing activity of nigra dopaminergic neurons in Parkinson's disease. Neurochemistry international vol issue 2022 36563966 parkinson's disease is the second most common neurodegenerative disease which is characterized by selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. 2022-12-23 2022-12-28 Not clear
Erl\\xc3\\xa2nia Alves de Siqueira, Emanuel Paula Magalh\\xc3\\xa3es, Ramon R\\xc3\\xb3seo Paula Pessoa Bezerra de Menezes, Tiago Lima Sampaio, Danya Bandeira Lima, Concei\\xc3\\xa7\\xc3\\xa3o da Silva Martins, Kelly Rose Tavares Neves, Gerly Anne de Castro Brito, Alice Maria Costa Martins, Glauce Socorro de Barros Vian. Vitamin D3 actions on astrocyte cells: a target for therapeutic strategy in Parkinson's disease? Neuroscience letters vol issue 2022 36470505 parkinson's disease (pd) is a neurodegenerative disease characterized by the loss of dopaminergic cells in the substantia nigra pars compacta. 2022-12-05 2022-12-08 Not clear
X\\xc3\\xb3chitl Flores-Ponce, Adolfo L\\xc3\\xb3pez-Ornelas, Itzel Escobedo-Avila, Mayela Rodr\\xc3\\xadguez-Violante, David D\\xc3\\xa1vila-Ortiz de Montellano, Am\\xc3\\xadn Cervantes-Arriaga, Nancy Monroy-Jaramillo, Iv\\xc3\\xa1n Velasc. Generation of a human induced pluripotent stem cell line (UNAMi001-A) from a Mexican patient with sporadic Parkinson's disease. Stem cell research vol 65 issue 2022 36427474 parkinson's disease (pd) is a neurodegenerative disease caused by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which results in motor alterations. 2022-11-25 2022-11-28 Not clear
Yao-Lin Li, Zhong-Xuan Wang, Chang-Zhou Ying, Bao-Rong Zhang, Jia-Li P. Decoding the Role of Familial Parkinson's Disease-Related Genes in DNA Damage and Repair. Aging and disease vol 13 issue 5 2022 36186134 parkinson's disease (pd) is a neurodegenerative disease characterized by the degeneration of midbrain substantia nigra pars compacta dopaminergic neurons and the formation of lewy bodies. 2022-10-03 2022-10-10 Not clear
Christian Ardianto, Robert Shen, Jimmy F A Barus, Poppy Kristina Sasmita, Yuda Turana, Lilis Lilis, Veronika Maria Sidhart. Secretome as neuropathology-targeted intervention of Parkinson's disease. Regenerative therapy vol 21 issue 2022 36092507 parkinson's disease (pd) is the second most common progressive neurodegenerative disease, characterized by apoptosis of dopaminergic neurons in substansia nigra pars compacta (snpc) caused by \xe2\x8d\xba-synuclein aggregation. 2022-09-12 2022-09-14 Not clear
Nicola Montemurro, Nelida Aliaga, Pablo Graff, Amanda Escribano, Jafeth Lizan. New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review. International journal of environmental research and public health vol 19 issue 14 2022 35886651 parkinson's disease (pd) is a progressive neurodegenerative disease, whose main neuropathological finding is pars compacta degeneration due to the accumulation of lewy bodies and lewy neurites, and subsequent dopamine depletion. 2022-07-27 2022-08-08 Not clear
Theodora Mourtzi, Ilias Kazani. Endogenous Neural regeneration research vol 17 issue 12 2022 35662194 endogenous parkinson's disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. 2022-06-06 2022-06-13 Not clear
Hung-Te Hsu, Ya-Lan Yang, Wan-Hsuan Chang, Wei-Yu Fang, Shu-Hung Huang, Shah-Hwa Chou, Yi-Ching L. Hyperbaric Oxygen Therapy Improves Parkinson's Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1\\xce\\xb1 Pathway. Biomolecules vol 12 issue 5 2022 35625589 pd is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-05-28 2022-06-13 Not clear
Deepika Np, Md Habibur Rahman, Sandhya Chipurupalli, Shilpa Tn, Basavan Duraiswam. Emerging Role of Marine Natural Products for the Treatment of Parkinson's Disease. CNS & neurological disorders drug targets vol issue 2022 35546747 parkinson's disease (pd), known as parkinsonism, is a neurodegenerative disease that mainly affects the elderly and is characterized by an extensive and progressive loss of dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-05-13 2022-06-13 Not clear
Jianjun Xu, Etsuko Minobe, Masaki Kameyam. Ca Frontiers in cellular neuroscience vol 16 issue 2022 35496903 ca parkinson's disease (pd), a common neurodegenerative disease characterized by motor dysfunction, results from the death of dopaminergic neurons in the substantia nigra pars compacta (snc). 2022-05-02 2022-05-03 Not clear
Katarzyna Kaczy\\xc5\\x84ska, Magdalena Ewa Or\\xc5\\x82owska, Kryspin Andrzejewsk. Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models? International journal of molecular sciences vol 23 issue 7 2022 35408858 parkinson's disease (pd) is the second most common progressive neurodegenerative disease characterized by movement disorders due to the progressive loss of dopaminergic neurons in the ventrolateral region of the substantia nigra pars compacta (snpc). 2022-04-12 2022-04-14 Not clear
Tao Dang, Wen-Jing Cao, Rong Zhao, Ming Lu, Gang Hu, Chen Qia. ATP13A2 protects dopaminergic neurons in Parkinson's disease: from biology to pathology. Journal of biomedical research vol issue 2022 35387901 as we all know, pd is a neurodegenerative disease characterized by the loss of da neurons in the substantia nigra pars compacta. 2022-04-07 2022-04-14 Not clear
Ruixian Xing, Xuewen Liu, Buxian Tian, Yan Cheng, Longguang L. Neuroprotective effect of Na Drug development research vol 82 issue 7 2021 33538000 neuroprotective effect of na parkinson's disease (pd) is a disabling neurodegenerative disease mainly caused by degeneration of mesencephalic dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-02-03 2022-01-13 Not clear
Ayumi E Pottenger, Mitchell J Bartlett, Scott J Sherman, Torsten Falk, Helena W Morriso. Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience letters vol 765 issue 2022 34536508 parkinson's disease (pd) is a neurodegenerative disease caused by the death of dopaminergic neurons in the substantia nigra pars compacta (snpc), characterized by motor dysfunction. 2022-01-10 2022-01-13 Not clear
Lan-Hsin Nancy Lee, Chen-Syuan Huang, Hsiang-Hao Chuang, Hsing-Jung Lai, Cheng-Kai Yang, Ya-Chin Yang, Chung-Chin Ku. An electrophysiological perspective on Parkinson's disease: symptomatic pathogenesis and therapeutic approaches. Journal of biomedical science vol 28 issue 1 2021 34886870 parkinson's disease (pd), or paralysis agitans, is a common neurodegenerative disease characterized by dopaminergic deprivation in the basal ganglia because of neuronal loss in the substantia nigra pars compacta. 2021-12-10 2022-01-13 Not clear
Hongli Li, Yaru Feng, Ziyu Chen, Xi Jiang, Zhenyu Zhou, Jinfeng Yuan, Fei Li, Yu Zhang, Xingxu Huang, Shengjie Fan, Xiaojun Wu, Cheng Huan. Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans. Pharmacological research vol 163 issue 2021 33007422 parkinson's disease (pd) is a progressive neurodegenerative disease resulting from the degeneration of dopaminergic (daergic) neurons in the substantia nigra pars compacta (snpc) and subsequent deficit of dopamine in the striatum. 2021-11-18 2022-01-13 Not clear
Ruixian Xing, Xuewen Liu, Buxian Tian, Yan Cheng, Longguang L. Neuroprotective effect of Na Drug development research vol 82 issue 7 2021 33538000 neuroprotective effect of na parkinson's disease (pd) is a disabling neurodegenerative disease mainly caused by degeneration of mesencephalic dopaminergic neurons in the substantia nigra pars compacta (snpc). 2021-11-15 2022-01-13 Not clear
Henrik Renner, Hans R Sch\\xc3\\xb6ler, Jan M Brude. Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond. Movement disorders : official journal of the Movement Disorder Society vol issue 2021 34498298 parkinson's disease (pd) is the second most common neurodegenerative disease and primarily characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. 2021-09-20 2022-01-13 Not clear
Page: 
1   2   3   4   5   6